山东大学学报（医学版） ›› 2017, Vol. 55 ›› Issue (1): 26-32.doi: 10.6040/j.issn.1671-7554.0.2016.1334
杨冬梓,麦卓瑶
YANG Dongzi, MAI Zhuoyao
摘要： 35岁后多囊卵巢综合征(PCOS)患者的卵巢储备较之同龄人可能有一定的优势。在行辅助生育技术(ART)过程中,40岁前的获卵数往往高于同龄非PCOS人群,40岁以后PCOS患者同样有卵泡质量及胚胎发育潜能不足的问题,对ART助孕结局产生不利影响。现有资料表明,PCOS患者在40岁以后的临床妊娠率、活产率与同龄非PCOS人群的变化趋势一样,同时其代谢、内分泌因素对妊娠结局的负面影响仍然存在。
中图分类号:
| [1] McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome[J]. N Engl J Med, 2016, 375(1): 54-64. [2] 沈文娟, 张跃辉, 匡洪影, 等. 多囊卵巢综合征治疗的研究现状[J]. 中华妇产科杂志, 2012, 47(1): 67-70. [3] Somigliana E, Paffoni A, Busnelli A, et al. Age-related infertility and unexplained infertility: an intricate clinical dilemma[J]. Hum Reprod, 2016, 31(7): 1390-1396. [4] Broekmans FJ, Knauff EA, te Velde ER, et al. Female reproductive ageing: current knowledge and future trends[J]. Trends Endocrinol Metab, 2007, 18(2): 58-65. [5] Richardson MC, Guo M, Fauser BC, et al. Environmental and developmental origins of ovarian reserve[J]. Hum Reprod Update, 2014, 20(3): 353-369. [6] te Velde ER, Scheffer GJ, Dorland M, et al. Developmental and endocrine aspects of normal ovarian aging[J]. Mol Cell Endocrinol, 1998, 145(1-2): 67-73. [7] Qiao J, Wang ZB, Feng HL, et al. The root of reduced fertility in aged women and possible therapentic options: current status and future perspects[J]. Mol Aspects Med, 2014, 38: 54-85. doi: 10.1016/j.mam.2013.06.001. [8] Rabinowitz M, Ryan A, Gemelos G, et al. Origins and rates of aneuploidy in human blastomeres[J]. Fertil Steril, 2012, 97(2): 395-401. [9] Monniaux D, Clement F, Dalbies-Tran R, et al. The ovarian reserve of primordial follicles and the dynamic reserve of antral growing follicles: what is the link?[J] Biol Reprod, 2014, 90(4): 85. doi: 10.1095/biolreprod.113.117077. [10] Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection[J]. Mol Hum Reprod, 2013, 19(8): 519-527. [11] Cui Y, Shi Y, Cui L, et al. Age-specific serum antimüllerian hormone levels in women with and without polycystic ovary syndrome[J]. Fertil Steril, 2014, 102(1): 230-236. [12] Aksglaede L, Sorensen K, Boas M, et al. Changes in anti-Mullerian hormone(AMH)throughout the life span: a population-based study of 1027 healthy males from birth(cord blood)to the age of 69 years[J]. J Clin Endocrinol Metab, 2010, 95(12): 5357-5364. [13] Wellons MF, Bates GW, Schreiner PJ, et al. Antral follicle count predicts natural menopause in a population-based sample: the Coronary Artery Risk Development in Young Adults Womens Study[J]. Menopause, 2013, 20(8): 825-830. [14] Hansen KR, Hodnett GM, Knowlton N, et al. Correlation of ovarian reserve tests with histologically determined primordial follicle number[J]. Fertil Steril, 2011, 95(1): 170-175. [15] Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies[J]. J Clin Endocrinol Metab, 2006, 91(5): 1660-1666. [16] Webber LJ, Stubbs S, Stark J, et al. Formation and early development of follicles in the polycystic ovary[J]. Lancet, 2003, 362(9389): 1017-1021. [17] Hudecova M, Holte J, Olovsson M, et al. Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve[J]. Hum Reprod, 2009, 24(5): 1176-1183. [18] Catteau-Jonard S, Jamin SP, Leclerc A, et al. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2008, 93(11): 4456-4461. [19] Tehrani FR, Solaymani-Dodaran M, Hedayati M, et al. Is polycystic ovary syndrome an exception for reproductive aging?[J]. Hum Reprod, 2010, 25(7): 1775-1781. [20] Wiser A, Shalom-Paz E, Hyman JH, et al. Age-related normogram for antral follicle count in women with polycystic ovary syndrome[J]. Reprod Biomed Online, 2013, 27(4): 414-418. [21] Webber LJ, Stubbs SA, Stark J, et al. Prolonged survival in culture of preantral follicles from polycystic ovaries[J]. J Clin Endocrinol Metab, 2007, 92(5): 1975-1978. [22] Schmidt J, Brannstrom M, Landin-Wilhelmsen K, et al. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome(PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls[J]. J Clin Endocrinol Metab, 2011, 96(7): 2178-2185. [23] Wild S, Pierpoint T, Jacobs H, et al. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study[J]. Hum Fertil(Camb), 2000, 3(2): 101-105. [24] May-Panloup P, Boucret L, Chao de la Barca JM, et al. Ovarian ageing: the role of mitochondria in oocytes and follicles[J]. Hum Reprod Update, 2016, 22(6):725-743. [25] Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence[J]. Hum Reprod Update, 2011, 17(1): 17-33. [26] Dumesic DA, Abbott DH. Implications of polycystic ovary syndrome on oocyte development[J]. Semin Reprod Med, 2008, 26(1): 53-61. [27] Dumesic DA, Padmanabhan V, Abbott DH. Polycystic ovary syndrome and oocyte developmental competence[J]. Obstet Gynecol Surv, 2008, 63(1): 39-48. [28] Wood JR, Dumesic DA, Abbott DH, et al. Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis[J]. J Clin Endocrinol Metab, 2007, 92(2): 705-713. [29] Heijnen EM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome[J]. Hum Reprod Update, 2006, 12(1): 13-21. [30] Sigala J, Sifer C, Dewailly D, et al. Is polycystic ovarian morphology related to a poor oocyte quality after controlled ovarian hyperstimulation for intracytoplasmic sperm injection? Results from a prospective, comparative study[J]. Fertil Steril, 2015, 103(1): 112-118. [31] Child TJ, Abdul-Jalil AK, Gulekli B, et al. In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome[J]. Fertil Steril, 2001, 76(5): 936-942. [32] Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest[J]. Hum Reprod Update, 2004, 10(2): 107-117. [33] Hughesdon PE. Morphology and morphogenesis of the stein-leventhal ovary and of so-called “hyperthecosis”[J]. Obstet Gynecol Surv, 1982, 37(2): 59-77. [34] Dewailly D, Catteau-Jonard S, Reyss AC, et al. The excess in 2-5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome[J]. Hum Reprod, 2007, 22(6): 1562-1566. [35] Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary[J]. Endocrinology, 2002, 143(3): 1076-1084. [36] Carlsson IB, Scott JE, Visser JA, et al. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro[J]. Hum Reprod, 2006, 21(9): 2223-2227. [37] Stubbs SA, Hardy K, Da Silva-Buttkus P, et al. Anti-müllerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries[J]. J Clin Endocrinol Metab, 2005, 90(10): 5536-5543. [38] Hsueh AJ, Kawamura K, Cheng Y, et al. Intraovarian control of early folliculogenesis[J]. Endocr Rev, 2015, 36(1): 1-24. [39] Bhide P, Dilgil M, Gudi A, et al. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimullerian hormone than its counterpart in a normal ovary: an observational cross-sectional study[J]. Fertil Steril, 2015, 103(2): 537-541. [40] Das M, Gillott DJ, Saridogan E, et al. Anti-mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome[J]. Hum Reprod, 2008, 23(9): 2122-2126. [41] Dewailly D, Robin G, Peigne M, et al. Interactions between androgens, FSH, anti-mullerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary[J]. Hum Reprod Update, 2016, 22(6):709-724. [42] Grossman MP, Nakajima ST, Fallat ME, et al. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture[J]. Fertil Steril, 2008, 89(5 Suppl): 1364-1370. [43] Pierre A, Peigne M, Grynberg M, et al. Loss of LH-induced down-regulation of anti-Mullerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome[J]. Hum Reprod, 2013, 28(3): 762-769. [44] Grynberg M, Pierre A, Rey R, et al. Differential regulation of ovarian anti-mullerian hormone(AMH)by estradiol through alpha- and beta-estrogen receptors[J]. J Clin Endocrinol Metab, 2012, 97(9): E1649-E1657. [45] Catteau-Jonard S, Pigny P, Reyss AC, et al. Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2007, 92(11): 4138-4143. [46] Xi W, Yang Y, Mao H, et al. Circulating anti-mullerian hormone as predictor of ovarian response to clomiphene citrate in women with polycystic ovary syndrome[J]. J Ovarian Res, 2016, 9: 3. [47] Koninger A, Sauter L, Edimiris P, et al. Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome[J]. Hum Reprod, 2014, 29(3): 518-524. [48] Mumford SL, Legro RS, Diamond MP, et al. Baseline AMH level associated with ovulation following ovulation induction in women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2016, 101(9): 3288-3296. [49] Ellakwa HE, Sanad ZF, Hamza HA, et al. Predictors of patient responses to ovulation induction with clomiphene citrate in patients with polycystic ovary syndrome experiencing infertility[J]. Int J Gynaecol Obstet, 2016, 133(1): 59-63. [50] Hudecova M, Holte J, Moby L, et al. Androgen levels, insulin sensitivity, and early insulin response in women with polycystic ovary syndrome: a long-term follow-up study[J]. Fertil Steril, 2011, 95(3): 1146-1148. [51] Guido M, Belosi C, Selvaggi L, et al. The effect of age on the ovarian response to gonadotropin and on pregnancy rate in polycystic ovary syndrome[J]. Gynecol Endocrinol, 2003, 17(3): 215-221. [52] Mellembakken JR, Berga SL, Kilen M, et al. Sustained fertility from 22 to 41 years of age in women with polycystic ovarian syndrome[J]. Hum Reprod, 2011, 26(9): 2499-2504. [53] Kalra SK, Ratcliffe SJ, Dokras A. Is the fertile window extended in women with polycystic ovary syndrome? Utilizing the society for assisted reproductive technology registry to assess the impact of reproductive aging on live-birth rate[J]. Fertil Steril, 2013, 100(1): 208-213. [54] Hwang YI, Cha SW, Song IO, et al. Fertility of patients with polycystic ovary syndrome undergoing in vitro fertilization by age[J]. Int J Gynaecol Obstet, 2016, 35(1):91-95. [55] Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome(OHSS): a review[J]. Hum Reprod Update, 2002, 8(6): 559-577. [56] Koivunen R, Pouta A, Franks S, et al. Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study[J]. Hum Reprod, 2008, 23(9): 2134-2139. [57] West S, Vahasarja M, Bloigu A, et al. The impact of self-reported oligo-amenorrhea and hirsutism on fertility and lifetime reproductive success: results from the Northern Finland Birth Cohort 1966[J]. Hum Reprod, 2014, 29(3): 628-633. [58] Dicker D, Goldman JA, Ashkenazi J, et al. Age and pregnancy rates in in vitro fertilization[J]. J In Vitro Fert Embryo Transf, 1991, 8(3): 141-144. [59] Dor J, Seidman DS, Ben-Shlomo I, et al. Cumulative pregnancy rate following in-vitro fertilization: the significance of age and infertility aetiology[J]. Hum Reprod, 1996, 11(2): 425-428. [60] Gonzalez-Foruria I, Penarrubia J, Borras A, et al. Age, independent from ovarian reserve status, is the main prognostic factor in natural cycle in vitro fertilization[J]. Fertil Steril, 2016, 106(2): 342-347. [61] Shea LO, Hughes C, Mocanu EV. Advanced maternal age and assisted reproductive technologies in an irish population[J]. Ir Med J, 2015, 108(8): 243-246. [62] Yan J, Wu K, Tang R, et al. Effect of maternal age on the outcomes of in vitro fertilization and embryo transfer(IVF-ET)[J]. Sci China Life Sci, 2012, 55(8): 694-698. |
| [1] | 丁祥云,于清梅,张文芳,庄园,郝晶. 胰岛素样生长因子II在84例多囊卵巢综合征患者颗粒细胞中的表达和促排卵结局的相关性[J]. 山东大学学报 (医学版), 2020, 1(7): 60-66. |
| [2] | 张素萍,王泽,周亚丽, 李敬,路西兰,柏宏伟,石玉华. 来曲唑治疗不同体质量指数多囊卵巢综合征患者的临床效果[J]. 山东大学学报（医学版）, 2017, 55(5): 81-85. |
| [3] | 李梅. 高龄女性的卵子和胚胎质量[J]. 山东大学学报（医学版）, 2017, 55(1): 16-21. |
| [4] | 陈子江. “二孩”生育政策后再生育的临床思考[J]. 山东大学学报（医学版）, 2017, 55(1): 1-4. |
| [5] | 邓晓惠,徐亚瑄. 高龄女性生育力评估及辅助生育[J]. 山东大学学报（医学版）, 2017, 55(1): 5-10. |
| [6] | 朱依敏. 高龄辅助生育技术子代出生缺陷及认知障碍的风险[J]. 山东大学学报（医学版）, 2017, 55(1): 11-15. |
| [7] | 石玉华,李敬. 高龄女性助孕措施选择[J]. 山东大学学报（医学版）, 2017, 55(1): 22-25. |
| [8] | 贾月月,刘洪彬,李婧博,李敬,张江涛, 孙梅,石玉华. 多囊卵巢综合征患者颗粒细胞microRNA-200b的表达及影响[J]. 山东大学学报（医学版）, 2017, 55(1): 63-68. |
| [9] | 李婧博,刘洪彬,贾月月,王泽,孙梅,石玉华. microRNA-183在PCOS胰岛素抵抗中的表达及其临床意义[J]. 山东大学学报（医学版）, 2017, 55(1): 69-74. |
| [10] | 张琳,李敬,王泽,张江涛,马增香,石玉华. 多囊卵巢综合征患者促甲状腺激素对血糖、血脂的影响[J]. 山东大学学报（医学版）, 2017, 55(1): 80-84. |
| [11] | 刘胜厚, 王韶进, 刘文广, 殷庆丰, 赵恒, 肖士鹏. 国产WagnerSL假体置换治疗高龄EvansⅢ型粗隆间骨折的疗效分析[J]. 山东大学学报（医学版）, 2015, 53(8): 49-52. |
| [12] | 王玮, 常康, 李晓冬, 郝桂敏. 胰岛素增敏剂对PCOS大鼠子宫内膜胰岛素受体底物表达的影响[J]. 山东大学学报（医学版）, 2014, 52(12): 24-29. |
| [13] | 王立葵, 桑洪爱, 马玉燕, 徐银涛, 王琳琳. 66例系统性红斑狼疮患者67次妊娠特点及妊娠结局分析[J]. 山东大学学报（医学版）, 2014, 52(12): 69-72. |
| [14] | 哈灵侠, 李向红. 多囊卵巢综合征患者卵泡液中GDF9和BMP15的表达及意义[J]. 山东大学学报（医学版）, 2014, 52(10): 77-80,95. |
| [15] | 哈灵侠1,2, 石玉华1, 赵君利2, 陈子江1. 宁夏地区多囊卵巢综合征患者不同雄激素状态脂代谢特点的比较性分析[J]. 山东大学学报(医学版), 2013, 51(9): 88-91. |
|
||
